Regeneron slump continues as analysts turn more cautious
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
Go back to Regeneron slump continues as analysts turn more cautious
September 26, 2024 5:56 AM EDT
Morgan Stanley analyst Matthew Harrison reiterated an Overweight rating and $1,247.00 price target on Regeneron Pharma (NASDAQ: REGN).
The analyst comments "Today the Federal Circuit issued an order to temporarily enjoin Amgen from launching its Eylea biosimilar until further notice. As a... More
September 25, 2024 5:43 AM EDT
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $320.00 price target on Amgen (NASDAQ: AMGN).
The analyst comments "Earlier this evening, Amgen (AMGN, Buy) provided positive Ph3 updates from two key pipeline programs - Uplizna in gMG and rocatinlimab in atopic... More
September 24, 2024 2:18 PM EDT
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $1,200.00 price target on Regeneron Pharma (NASDAQ: REGN)
The analyst comments "We spoke with Regeneron (REGN, Buy) mgmt today who noted that they have appealed the court's decision as of last night, and... More
